| G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer. We show 24 historical shares outstanding datapoints in our GTHX shares outstanding history coverage, used to compute GTHX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GTHX market cap history over the course of time is important for investors
interested in comparing GTHX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GTHX versus a peer is one thing; comparing
GTHX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GTHX can fluctuate over the course of history.
With this page we aim to empower investors researching GTHX by allowing them to research the GTHX market cap history.